New study reveals hidden heart risks of common breast cancer drug

NCT ID NCT06781762

First seen Nov 01, 2025 · Last updated May 15, 2026 · Updated 26 times

Summary

This study tracks 40 women with hormone-positive breast cancer who are starting aromatase inhibitor therapy, comparing them to healthy women of similar age and weight. Researchers want to understand how this common treatment affects the heart, blood vessels, metabolism, and lifestyle in the first 6 months. The goal is to identify early warning signs of heart problems so doctors can better protect patients.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for BREAST CANCER FEMALES are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • University of Toronto

    RECRUITING

    Toronto, Ontario, M5S2C9, Canada

    Contact Phone: •••-•••-•••• Email: •••••@•••••

Conditions

Explore the condition pages connected to this study.